There are thousands of promising drugs for treating diseases that are simply not getting studied or brought to market because they are derived from natural or common substances that can't be patented. The dirty little secret of the pharma business is that
Big Pharma is also showing interest for this emerging market and an example which illustrates this attention is the deal that Merck KGaA has just signed with Chi-Med under which the German drugmaker will develop new cancer treatments using traditional Chi